Immunomodulatory Compounds for Leptin Secretion in Lipodystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for disorders associated with low plasma leptin levels, such as lipodystrophy and anorexia nervosa, are ineffective in managing severe metabolic issues and are cumbersome due to daily intravenous administration and inability to mimic natural leptin fluctuations.
Innovation Solution
Development of immunomodulatory compounds, specifically 1-oxo- and 1,3-dioxo-(2,6-dioxopiperidin-3-yl) isoindolines, which inhibit TNF-α production, enhance leptin secretion, and are administered in combination with other therapies to manage hypoleptinemic states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant leptin is used for replacement therapy, then leptin levels are restored, but the treatment becomes painful and bothersome due to daily intravenous administrations
Solution Approach 1:
The patent introduces immunomodulatory compounds as intermediary substances that act on the leptin production pathway. These compounds stimulate adipocytes to endogenously produce leptin, thereby reducing or eliminating the need for daily intravenous recombinant leptin administration while still achieving the therapeutic effect of restoring leptin levels.
Solution Approach 2:
The therapy shifts from exogenous leptin replacement to stimulating the body's own leptin production. By using immunomodulatory compounds to activate adipocytes, the body's natural leptin production system is engaged, making the treatment more convenient and reducing the burden of daily intravenous injections.
2Reliability
If recombinant leptin is used for replacement therapy, then constant doses are provided, but this differs significantly from the natural fluctuation of leptin levels in the body
Solution Approach 1:
The patent employs immunomodulatory compounds that dynamically regulate leptin production rather than providing static constant dosing. The compounds modulate the body's natural leptin secretion rhythm, allowing leptin levels to fluctuate in a controlled manner that mimics natural circadian patterns while maintaining therapeutic effectiveness.
3Productivity
If known therapies are used for lipodystrophy, then some metabolic issues are addressed, but patients continue to have severe hyperglyceridemia leading to recurrent attacks of acute pancreatitis
Solution Approach 1:
The patent employs immunomodulatory compounds that exert multiple therapeutic effects simultaneously. These compounds not only address leptin deficiency but also have broader metabolic regulatory effects, including improvement of lipid metabolism and reduction of hyperglyceridemia, thereby treating multiple aspects of lipodystrophy syndrome with a single therapeutic approach.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3C
AI summary
Methods of treating, preventing and/or managing disorders associated with low plasma leptin levels are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.